Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 142Gastrointestinal 32Breast 27Head & Neck 26Genitourinary 25Thoracic 23Dermatologic 15Sarcoma 8Other solid neoplasm 6CNS 5Other hematologic neoplasm 4Lymphoid 4NET 2Endocrine 2Plasma cell 1

Conditions

Multiple Myeloma 295Lymphoma 47Recurrence 29Neoplasms, Plasma Cell 28Hematologic Neoplasms 26Lymphoma, Non-Hodgkin 21Smoldering Multiple Myeloma 20Neoplasms 13Leukemia, Lymphocytic, Chronic, B-Cell 11Immunoglobulin Light-chain Amyloidosis 11Myelodysplastic Syndromes 10Leukemia 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Myeloid, Acute 9Hodgkin Disease 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Lymphoma, Mantle-Cell 6Prostatic Neoplasms 5Paraproteinemias 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Breast Neoplasms 5Lymphoproliferative Disorders 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Diseases 4Colorectal Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Anemia, Aplastic 4

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Uterine Cervical Neoplasms × Plasma cell × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡